Protocol
Multi-domain diet and lifestyle program with supplements (8 weeks, as studied)
One pilot randomized trial in 43 healthy men aged 50 to 72 tested an 8-week program of diet, sleep, exercise and relaxation guidance plus a probiotic and a phytonutrient powder, against no intervention.
Grade C: human trials exist, but they are small, mixed or not yet repeated. This is not a finding that it does not work. How to read a grade →
At a glance
This program combined diet, exercise, sleep and stress changes with two supplements for 8 weeks. One small study included 43 men aged 50 to 72. In the men on the program, a saliva test meant to estimate body age came out lower than in men who made no changes. The change within the program group alone was not clear. Part of the gap came from the other group's estimated age going up.
- What was measured
- Estimated body age from a saliva test (a DNA methylation clock) after an 8 week program.
- How big
- The program group's saliva age came out 3.23 years lower than the control group's. The drop within the program group alone, 1.96 years, was not clearly real.Read from the summary of PMID PubMed ID: the permanent number the US National Library of Medicine gives a published paper. Each one links to that paper's record on PubMed. 33844651.
- Who it applies to
- 43 healthy men aged 50 to 72. No women were in the trial, and the maker of the program's two supplements supported it.
- Safety
- This record lists no specific safety warning for the program.
- Compared with
- A group that made no changes.
- Certainty
- Grade C, resting on: One pilot randomized controlled trial People are assigned to the treatment or a comparison by chance, so the groups differ only in what they received. It is the design that can show cause and effect., maker-funded.
- What would change this grade
- Could rise to A with: Two or more randomized controlled trials of the 8-week program against an active control, each run by a group independent of the program's developers and of each other. Who: Adults aged 50 to 72, at least 100 per arm. Measured: A clinical or instrument-measured functional outcome as the primary endpoint The one outcome a trial names in advance as its main test. Results on other outcomes carry less weight., such as measured grip strength, gait speed or VO2max The most oxygen the body can use during all-out exercise, a standard measure of aerobic fitness., with epigenetic age on a preregistered clock as a secondary measure. Length: 8 weeks, with follow-up to 12 months.
- Cost
- No price recorded yet.
- Sources
- 4 studies cited on this record, listed under Sources.
One pilot randomized trial in 43 healthy men aged 50 to 72 tested an 8-week program of diet, sleep, exercise and relaxation guidance plus a probiotic and a phytonutrient powder, against no intervention. Saliva DNA methylation age on the 2013 Horvath clock was 3.23 years lower than in controls (p=0.018); the within-group fall of 1.96 years was not significant (p=0.066), so the result is a between-group difference, not a demonstrated reversal. The trial was funded by the maker of the two supplements, and the paper has two published corrections. No randomized trial has repeated the program; the authors' follow-up in women was an uncontrolled case series of six. Pilot-sized, single trial, surrogate endpoint A lab value or measurement used in place of the outcome that matters, such as LDL cholesterol standing in for heart attacks. Moving a surrogate does not always move the outcome.: C.
Why this letter
Why this gradeGrade C, small or unreplicated trials. The reasoning, and what the grade does not cover.
Grade C, resting on one small pilot randomized trial of an 8-week diet and lifestyle program that also included two supplements, reporting a lower saliva DNA methylation age than no-intervention controls in 43 men aged 50 to 72 (Fitzgerald et al., 2021; PMID 33844651). The within-group change was not significant, the control group's clock age rose in 8 weeks, and the paper carries two published corrections (PMID 35907207, PMID 38488762). It has not been independently replicated The same finding reproduced by a separate research group. A result seen once can be chance or bias; a replicated one is harder to explain away.: the authors' own follow-up in women (PMID 36947707) was an uncontrolled case series. Other randomized trials that moved epigenetic clocks A test that estimates biological age from chemical marks on DNA (DNA methylation). tested different interventions in different populations and cannot replicate this one. The endpoint The outcome a trial measures to decide whether the treatment worked, such as heart attacks, blood pressure or a symptom score. is a first-generation clock in saliva, a surrogate whose link to clinical outcomes is unsettled. The trial was supported by the maker of the two supplements in the program, and the lead authors use the program commercially.
WHAT THIS GRADE DOES NOT COVERbiological aging as a clinical outcome, lifespan, women (none were randomized), lifestyle change without the supplements, or any single component of the program tested on its own.
A grade describes the human evidence for a named use. It is not advice, and it is not a judgment on any individual prescription. How the letters are decided →
Who responds: this record's trial reading reports no subgroup that identifies who responds.
Evidence notes: randomized trial, pilot study, not independently replicated
Endpoint graded: DNA methylation age, an epigenetic clock (surrogate)
Last reviewed: October 2026
The trial that would change this grade.
Positive trials of this shape from independent research groups would move this entry to A.
Why the current trials fall short
The grade rests on one pilot trial of 43 men that carries two published corrections, on an epigenetic clock whose link to clinical outcomes is unsettled. A replication on the clock alone would stay at C, because the clock is not an established stand-in for a clinical outcome. No trial has measured a clinical or instrument-measured functional outcome, so one such trial would stand alone at C; independent trials that agree on that outcome are what is missing.
Why people believe itOne human source; no published case reports of benefit; no reports of harm.
The case for this program is that diet, sleep, exercise and relaxation, with nutrients that supply methyl groups, can reset DNA methylation, the chemical tags that epigenetic clocks read to estimate biological age. A pilot trial reported clock ages about 3 years younger than controls after 8 weeks, which drew wide coverage.
What supporters point to, and what each source actually shows. None of it is enough to move this letter higher; the trial described above under Evidence wanted is what would.
- Human study, no comparison groupIn six women who completed the 8-week program, five had a lower clock age afterward, by 1.2 to 11 years, and the group average fell by about 4.6 years. No comparison group, from the same authors as the pilot trial. PMID 36947707
A case report describes what happened to one or a few patients. It cannot show the treatment caused the change, and reports of success are published more often than reports of failure.
A PubMed search in October 2026 found no published case report of benefit for this use.
Searched PubMed, October 2026: 3 case report record(s) returned. None concerns this program: one is a pilot study of a rice bran supplement on an epigenetic clock, one describes blood vessel aging in survivors of a wartime siege, and one concerns forensic identification.
ClinicalTrials.gov, the public registry run by the U.S. National Library of Medicine, lists studies that are recruiting volunteers. The link below searches it for Multidomain Lifestyle Intervention among studies recruiting now. EBL has no relationship with any listed study and receives no payment for this link.
Search recruiting studies of Multidomain Lifestyle Intervention on ClinicalTrials.gov
Each marker links to its entry on the Longevity Lab Panel, which lists every graded record whose trials measured it. Moving a marker is not the same as preventing disease.
- Epigenetic age (DNA methylation clock) (Grade C for this use)
Each links to the hallmark's list on the Hallmarks of Aging page. The letter grades the outcome the trials measured, not the hallmark itself.
- Epigenetic alterations (Grade C for this use)
Dose, form and timing
The trial's endpoint was a saliva DNA methylation clock at baseline and 8 weeks; no cognitive or cardiometabolic composite was measured. A clock reading is comparable only with the same clock and tissue at both points. Adherence to each component (diet, sleep schedule, exercise, relaxation, supplements) in a diary is the process measure, since the trial did not test them apart.
Safety
No safety data. Each caution on this record, sorted by what it rests on.
None recorded.
None recorded.
None recorded.
None recorded.
No safety data: EBL has found no trial or report of harm for this record. That is an absence of evidence, not a finding of safety.
Grade history
How this letter has changedLatest: No. 236 · October 2026 · Corrected.
The description said one trial reported reversal of an epigenetic clock. The trial (Fitzgerald et al., Aging, 2021; PMID 33844651) randomized 43 men aged 50 to 72 to a program that included two supplements from the funder; the within-group change was not significant (p=0.066) and only the between-group difference was (p=0.018), so reversal overstated it. The record now names the clock (the 2013 Horvath clock, in saliva), the population, the supplements, the two published corrections (PMID 35907207, PMID 38488762) and the authors' uncontrolled case series in six women (PMID 36947707), which is not a replication. The track field, which described a FINGER-style cognitive battery the trial never measured, now follows the trial's own endpoint. In the pattern applied to other protocols the name states what was studied. C unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).PMID 33844651 PMID 35907207 PMID 36947707 PMID 38488762
Funding stated in the evidence. The single pilot trial, Fitzgerald 2021 (PMID 33844651), was supported by an unrestricted grant from the company that makes the two supplements in the program, and its two lead authors use the program in practice, hold a related patent application and earn from its educational products. Letter unchanged.PMID 33844651
Every change to a letter on this site is dated and published. The full evidence log →
Sources
- Citations
- Every paper cited on this page is matched to its PubMed record on every build.
- Retractions
- None of these papers is retracted or under a journal expression of concern. PubMed is checked again on every build.
- Read against the papers
- October 2026. By a language model (AI-assisted reading), not yet reviewed by a clinician.
- Outside review
- Not yet done. No reviewer outside EBL has checked this record.
What each of these checks can and cannot show: evidence integrity.
The evidence, in fullFour papers, each linked to its PubMed record.
Fitzgerald et al. (Aging, 2021; PMID 33844651): pilot randomized controlled trial, 43 healthy men aged 50 to 72, 8-week program of diet, sleep, exercise and relaxation guidance with supplemental probiotics and phytonutrients, against no intervention; saliva Horvath 2013 DNA methylation age 3.23 years lower than controls (p=0.018), within-group change 1.96 years, not significant (p=0.066); serum 5-methyltetrahydrofolate up and triglycerides down. Two corrections have been published (Aging, 2022; PMID 35907207; Aging, 2024; PMID 38488762). Fitzgerald et al. (Aging, 2023; PMID 36947707): the same program in six women, an uncontrolled case series, so not a replication. The endpoint is an epigenetic clock, a surrogate whose relationship to clinical outcomes is unsettled. Grade C reflects small single-trial human data. Funding: the paper states the trial was supported by an unrestricted grant from the company that makes the two supplements in the intervention arm, and that the two lead authors use the program in clinical practice, are named on a related patent application and earn from educational products associated with it, while stating they were not involved in day-to-day conduct, sample collection or analysis.
How EBL searched for the trials (1 search)
The search that was run, what it returned, and what was left out and why, so the absence of evidence can be checked as well as its presence.
(lifestyle[tiab] OR diet[tiab]) AND ("epigenetic age"[tiab] OR "DNA methylation age"[tiab] OR "epigenetic clock"[tiab] OR "biological age"[tiab]) AND randomized controlled trial[pt]PubMed watch: does a new study change the grade? (nothing new)
No new paper matching the search behind this grade has been added to PubMed since October 2026.
Last run October 2026. A letter on EBL moves only after a logged review. A new paper never moves a letter by arriving: it is read, the answer is written here, and any change to the letter is published in the evidence log.
Disclosure
Educational use only · Not medical advice · EBL grades published human evidence and does not recommend treatment. Stopping a prescription is a decision for your physician.
Evidence Based Longevity, Inc. is owner-operated and edited by Arnold Sandlow, D.C., a California-licensed chiropractor. Evidence Based Longevity publishes in English only · Machine translations are not produced or reviewed by EBL for accuracy
© Evidence Based Longevity, Inc. All rights reserved
These statements have not been evaluated by the Food and Drug Administration. Any grade on this page describes the strength of published human trial evidence in the populations studied. It is not a recommendation for any individual and is not medical advice. Starting, stopping or changing any supplement or medication is a decision for your physician.
Grades move when new trials publish. A free monthly email lists every grade EBL moved, with the reason and the trial behind it: the sign-up is on the Evidence Log →